BD’s revenue will match growth for the pre-filled injection device market to 2023

Thursday 2 May 2013, Amsterdam

In 2013, BD is the largest manufacturer of pre-filled injection devices, accounting for more than 50% of that market. The company will retain its position as the market leader throughout the period 2013-2023, with product revenue growing with a similar CAGR to the market as a whole for that period. In 2013, BD’s pharmaceutical systems revenue will grow to $1,133m, up from $1,074m in 2012. These findings appear in Pharma Leader Series: Top Pre-Filled Injection Device Manufacturers 2013-2023, published in March 2013.

Our forecasts faster revenue growth for other leading pre-filled injection device manufacturers, particularly those operating in the pen injector and autoinjector submarket. Rising demand for at-home healthcare solutions will drive revenue growth in this sector for these companies, which include Owen Mumford, SHL Group, Haselmeier and Ypsomed. Owen Mumford’s revenue for pen injectors and autoinjectors will double by 2018, for example. During the period 2013-2023, though, these companies will be challenged by many other competitors. This is the most fragmented sector of the pre-filled injection device market. As well as dedicated pen injector manufacturers, other competitors include pre-filled syringe manufacturers, including BD and Gerresheimer, pharmaceutical companies and specialist medical device contract manufacturing organisations (CMOs).              

Our new report profiles 15 leading device manufacturers and CMOs operating across four sectors of the pre-filled injection devices market:

• Pre-filled syringe manufacturers
• Pre-filled syringe component manufacturers
• Pen injector and autoinjector manufacturers
• Contract manufacturers providing filling services for pre-filled syringes.

For each of the leading companies, the report provides an overview of the product portfolio, an analysis of recent financial performance and developments in the sector. The report also identifies the strengths, weaknesses, opportunities and threats facing each company in this market for the period 2013-2023. Our forecasts pre-filled injection device revenue for that period for ten of the market leaders. The report analyses how each of the leading companies is responding to trends from the pharmaceutical industry and other trends in healthcare.

Richard Lang, a pharmaceutical market analyst, said: “Pre-filled injection device market leaders are all affected by the same trends from the pharmaceutical industry. However, it is clear that many are adopting unique strategies in reaction to these trends. Almost all market leaders are expanding in emerging markets, for example. While some are focused on the fastest-growing markets, such as India and China, others have chosen to grow in South America and CEE countries.

“Other trends that will become increasingly important for pre-filled injection device manufacturers in the coming decade include the rising development of biologics and biosimilars and the demands for high quality medical devices. Most companies now market devices, components and services targeted at biopharmaceutical drug developers. In order to increase market share, though, these companies must ensure that their products are easily differentiated from their competitors, while still meeting the developing demands of pharmaceutical companies.”